VEGF is associated with neovascularization and influences progression of NSCLC [14], and inhibition of VEGF or its receptor (VEGFR) correlate with impaired cell-cycle distribution, overall survival, and chemotherapy response [15, 16]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.